Home/Pipeline/BriDGE-based Wound Care

BriDGE-based Wound Care

Difficult-to-Heal Chronic Skin Wounds (e.g., Diabetic Foot Ulcers)

CommercialActive

Key Facts

Indication
Difficult-to-Heal Chronic Skin Wounds (e.g., Diabetic Foot Ulcers)
Phase
Commercial
Status
Active
Company

About Harbor MedTech

Harbor MedTech is a privately held, commercial-stage company developing regenerative medicine solutions for soft tissue repair. Its core asset is the BriDGE® technology, a proprietary collagen processing method that creates a matrix shown in studies to accelerate healing, support regeneration, and exhibit antimicrobial properties. The company currently has two FDA-cleared and CE-marked products and is advancing a pipeline targeting sports medicine, hernia/breast reconstruction, and chronic wounds. Harbor MedTech operates as a fully integrated entity, positioning itself to capture value in the growing orthopedic biologics and advanced wound care markets.

View full company profile